Drug Trial Radar · NCT06300411
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jul 29, 2024
Primary completion
Apr 8, 2026
Study completion Apr 8, 2026
Sponsor
- Lead sponsor
- SURGE TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Conditions
- Breast Cancer
Interventions
SRG-514Drug
SRG-514 monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]Time frame: 14 days
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Time on trial up to 60 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Memorial Health
Savannah, Georgia
Indiana University
Indianapolis, Indiana
Mayo
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
NYU Langone Health
New York, New York
Duke Cancer Center
Durham, North Carolina
MD Anderson Cancer Center
Houston, Texas
Audie Murphy VA
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.